Closed-Loop Insulin Pumps Help Pregnant Women with Type 1 Diabetes Keep Blood Sugar Stable

Pregnancy with Type 1 diabetes presents unique challenges. About half of pregnant women with Type 1 diabetes experience complications related to high blood sugar. Keeping glucose levels stable during pregnancy is critical because it protects both the pregnant person and the developing baby. This is where automated insulin delivery—closed-loop pumps—shows promise.

Closed-loop systems use a continuous glucose monitor and a computer algorithm to automatically adjust insulin doses throughout the day and night. The pump responds to changing glucose levels without requiring the user to manually calculate and deliver each dose. For pregnant women, this constant fine-tuning can help maintain steadier blood sugar levels across the entire pregnancy.

Multiple large clinical trials have now tested closed-loop systems in pregnant women with Type 1 diabetes. In a UK-based study of 124 pregnant women, those using closed-loop therapy spent 68% of the time in their target pregnancy glucose range (63-140 mg/dL), compared to 56% in the standard care group—a difference of about 10 percentage points.

A more recent Canadian and Australian trial, called CIRCUIT, enrolled 91 pregnant women and found similar results. Women using closed-loop therapy spent 65% of the time in target range compared to 50% in standard care—a 12.5 percentage point difference. Both studies tracked glucose levels from mid-pregnancy through delivery.

These improvements matter because time spent in the target range directly relates to better pregnancy outcomes. Women using closed-loop systems also spent less time in high blood sugar states, which is particularly important during pregnancy.

A key question for any new therapy is whether it introduces new risks. The clinical trials tracked serious safety events, including severe hypoglycemia (dangerously low blood sugar) and diabetic ketoacidosis (a serious metabolic complication). The data shows that closed-loop systems do not increase the risk of these events compared to standard insulin therapy.

Across the trials, severe hypoglycemia and diabetic ketoacidosis occurred at similar rates in both closed-loop and standard care groups. This is reassuring evidence that automated insulin delivery does not create unexpected safety problems during pregnancy, though as with any medical technology, individual experiences may vary.

Several closed-loop systems are now available or under development, including Minimed 670G, Minimed 780G, Control-IQ, CamAPS Fx, and Omnipod 5. Research comparing these systems shows they do not all perform identically. A systematic review of 28 clinical trials found that some systems achieved higher time in target range than others, though all performed better than older insulin delivery methods.

Because closed-loop technology is still evolving, it's important to have an open conversation with your care team about which system might be right for your situation. Your healthcare providers can discuss the evidence for each option, consider your personal preferences and medical history, and help you make an informed decision about whether closed-loop therapy is appropriate for you during pregnancy.

Closed-loop insulin systems represent an important tool for improving blood sugar management during Type 1 diabetes pregnancy. The evidence from multiple clinical trials consistently shows benefits in time spent in target range without increasing serious safety risks. However, this is an evolving field—research is ongoing, and new systems continue to be developed and tested.

If you are pregnant or planning pregnancy with Type 1 diabetes, speak with your endocrinologist or maternal-fetal medicine specialist about whether a closed-loop system might be helpful for you. They can review the latest evidence, discuss how it fits into your overall care plan, and help you weigh the benefits and practical considerations of this technology.

Origin: YouTube / Type1Cure (Video report). Evidence: Video report, corroborated with 6 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.